{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:33:30Z","timestamp":1790127210405,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,26]]},"DOI":"10.7759\/cureus.44167","type":"journal-article","created":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T15:45:36Z","timestamp":1693064736000},"source":"Crossref","is-referenced-by-count":2,"title":["Association of Medication-Assisted Therapy and Risk of Drug Overdose-Related Hospitalization or Emergency Room Visits in Patients With Opioid Use Disorder"],"prefix":"10.7759","author":[{"given":"Korosh","family":"Bahrami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Fang","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biai","family":"Digbeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukaila A","family":"Raji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"National Institute on Drug Abuse. Drug overdose death rates. (2023). Accessed. June 27, 2023: https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7326\/M20-1210","article-title":"When epidemics collide: coronavirus disease 2019 (COVID-19) and the opioid crisis","volume":"173","author":"Becker WC","year":"2020","unstructured":"Becker WC, Fiellin DA. When epidemics collide: coronavirus disease 2019 (COVID-19) and the opioid crisis. Ann Intern Med. 2020, 173:59-60. 10.7326\/M20-1210","journal-title":"Ann Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1058-y","article-title":"Healthcare costs and utilization associated with high-risk prescription opioid use: a retrospective cohort study","volume":"16","author":"Chang HY","year":"2018","unstructured":"Chang HY, Kharrazi H, Bodycombe D, Weiner JP, Alexander GC. Healthcare costs and utilization associated with high-risk prescription opioid use: a retrospective cohort study. BMC Med. 2018, 16:69. 10.1186\/s12916-018-1058-y","journal-title":"BMC Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2020.1784363","article-title":"COVID-19 and persons with substance use disorders: inequities and mitigation strategies","volume":"41","author":"Melamed OC","year":"2020","unstructured":"Melamed OC, Hauck TS, Buckley L, Selby P, Mulsant BH. COVID-19 and persons with substance use disorders: inequities and mitigation strategies. Subst Abus. 2020, 41:286-91. 10.1080\/08897077.2020.1784363","journal-title":"Subst Abus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0270582","article-title":"Mixed methods prospective findings of the initial effects of the U.S. COVID-19 pandemic on individuals in recovery from substance use disorder","volume":"17","author":"Shircliff K","year":"2022","unstructured":"Shircliff K, Liu M, Prestigiacomo C, et al.. Mixed methods prospective findings of the initial effects of the U.S. COVID-19 pandemic on individuals in recovery from substance use disorder. PLoS One. 2022, 17:e0270582. 10.1371\/journal.pone.0270582","journal-title":"PLoS One"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.0001","article-title":"Opioid agonist treatment for patients with dependence on prescription opioids","volume":"317","author":"Nielsen S","year":"2017","unstructured":"Nielsen S, Larance B, Lintzeris N. Opioid agonist treatment for patients with dependence on prescription opioids. JAMA. 2017, 317:967-8. 10.1001\/jama.2017.0001","journal-title":"JAMA"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo L","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, et al.. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017, 357:j1550. 10.1136\/bmj.j1550","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study","volume":"169","author":"Larochelle MR","year":"2018","unstructured":"Larochelle MR, Bernson D, Land T, et al.. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018, 169:137-45. 10.7326\/M17-3107","journal-title":"Ann Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/jrh.12307","article-title":"Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update","volume":"35","author":"Andrilla CH","year":"2019","unstructured":"Andrilla CH, Moore TE, Patterson DG, Larson EH. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update. J Rural Health. 2019, 35:108-12. 10.1111\/jrh.12307","journal-title":"J Rural Health"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.03.029","article-title":"Medication-assisted treatment for opioid-use disorder","volume":"94","author":"Oesterle TS","year":"2019","unstructured":"Oesterle TS, Thusius NJ, Rummans TA, Gold MS. Medication-assisted treatment for opioid-use disorder. Mayo Clin Proc. 2019, 94:2072-86. 10.1016\/j.mayocp.2019.03.029","journal-title":"Mayo Clin Proc"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.3673","article-title":"Racial and ethnic disparities in buprenorphine treatment duration in the US","volume":"80","author":"Dong H","year":"2023","unstructured":"Dong H, Stringfellow EJ, Russell WA, Jalali MS. Racial and ethnic disparities in buprenorphine treatment duration in the US. JAMA Psychiatry. 2023, 80:93-5. 10.1001\/jamapsychiatry.2022.3673","journal-title":"JAMA Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.06.006","article-title":"Treatment outcome disparities for opioid users: are there racial and ethnic differences in treatment completion across large US metropolitan areas?","volume":"190","author":"Stahler GJ","year":"2018","unstructured":"Stahler GJ, Mennis J. Treatment outcome disparities for opioid users: are there racial and ethnic differences in treatment completion across large US metropolitan areas?. Drug Alcohol Depend. 2018, 190:170-8. 10.1016\/j.drugalcdep.2018.06.006","journal-title":"Drug Alcohol Depend"},{"key":"ref13","unstructured":"Information about medication-assisted treatment. (2023). Accessed. June 27, 2023: https:\/\/www.fda.gov\/drugs\/information-drug-class\/information-about-medication-assisted-treatment-mat."},{"key":"ref14","unstructured":"SAS Institute Inc. Assessment of the proportional hazards model. (2019). Accessed. January 29, 2023: https:\/\/documentation.sas.com\/doc\/en\/pgmsascdc\/9.4_3.4\/statug\/statug_phreg_details75.htm."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019","volume":"110","author":"Krawczyk N","year":"2022","unstructured":"Krawczyk N, Rivera BD, Jent V, Keyes KM, Jones CM, Cerd\u00e1 M. Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019. Int J Drug Policy. 2022, 110:103786. 10.1016\/j.drugpo.2022.103786","journal-title":"Int J Drug Policy"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.6373","article-title":"Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder","volume":"2","author":"Haffajee RL","year":"2019","unstructured":"Haffajee RL, Lin LA, Bohnert AS, Goldstick JE. Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder. JAMA Netw Open. 2019, 2:e196373. 10.1001\/jamanetworkopen.2019.6373","journal-title":"JAMA Netw Open"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2019.05.002","article-title":"Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: addressing a critical care gap","volume":"103","author":"Krawczyk N","year":"2019","unstructured":"Krawczyk N, Buresh M, Gordon MS, Blue TR, Fingerhood MI, Agus D. Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: addressing a critical care gap. J Subst Abuse Treat. 2019, 103:1-8. 10.1016\/j.jsat.2019.05.002","journal-title":"J Subst Abuse Treat"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201600110","article-title":"The Mental Health Parity and Addiction Equity Act (MHPAEA) evaluation study: impact on quantitative treatment limits","volume":"68","author":"Thalmayer AG","year":"2017","unstructured":"Thalmayer AG, Friedman SA, Azocar F, Harwood JM, Ettner SL. The Mental Health Parity and Addiction Equity Act (MHPAEA) evaluation study: impact on quantitative treatment limits. Psychiatr Serv. 2017, 68:435-42. 10.1176\/appi.ps.201600110","journal-title":"Psychiatr Serv"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2017.03.006","article-title":"Chronic pain among patients with opioid use disorder: results from electronic health records data","volume":"77","author":"Hser YI","year":"2017","unstructured":"Hser YI, Mooney LJ, Saxon AJ, Miotto K, Bell DS, Huang D. Chronic pain among patients with opioid use disorder: results from electronic health records data. J Subst Abuse Treat. 2017, 77:26-30. 10.1016\/j.jsat.2017.03.006","journal-title":"J Subst Abuse Treat"},{"key":"ref20","article-title":"Cost and utilization outcomes of opioid-dependence treatments","volume":"17","author":"Baser O","year":"2011","unstructured":"Baser O, Chalk M, Fiellin DA, Gastfriend DR. Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care. 2011, 17:S235-48.","journal-title":"Am J Manag Care"},{"key":"ref21","unstructured":"National Institute on Drug Abuse. How effective are medications to treat opioid use disorder?. (2021). Accessed. June 27, 2023: https:\/\/nida.nih.gov\/publications\/research-reports\/medications-to-treat-opioid-addiction\/efficacy-medications-opioid-...."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.23032","article-title":"Comparison of treatment retention of adults with opioid addiction managed with extended-release buprenorphine vs daily sublingual buprenorphine-naloxone at time of release from jail","volume":"4","author":"Lee JD","year":"2021","unstructured":"Lee JD, Malone M, McDonald R, et al.. Comparison of treatment retention of adults with opioid addiction managed with extended-release buprenorphine vs daily sublingual buprenorphine-naloxone at time of release from jail. JAMA Netw Open. 2021, 4:e2123032. 10.1001\/jamanetworkopen.2021.23032","journal-title":"JAMA Netw Open"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-022-00288-4","article-title":"Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study","volume":"17","author":"Cheng A","year":"2022","unstructured":"Cheng A, Badolato R, Segoshi A, et al.. Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study. Addict Sci Clin Pract. 2022, 17:4. 10.1186\/s13722-022-00288-4","journal-title":"Addict Sci Clin Pract"},{"key":"ref24","article-title":"Buprenorphine therapy for opioid use disorder","volume":"97","author":"Zoorob R","year":"2018","unstructured":"Zoorob R, Kowalchuk A, Mejia de Grubb M. Buprenorphine therapy for opioid use disorder. Am Fam Physician. 2018, 97:313-20.","journal-title":"Am Fam Physician"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4103\/0976-3147.91934","article-title":"Buprenorphine vs methadone treatment: a review of evidence in both developed and developing worlds","volume":"3","author":"Whelan PJ","year":"2012","unstructured":"Whelan PJ, Remski K. Buprenorphine vs methadone treatment: a review of evidence in both developed and developing worlds. J Neurosci Rural Pract. 2012, 3:45-50. 10.4103\/0976-3147.91934","journal-title":"J Neurosci Rural Pract"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxz105","article-title":"Medications for management of opioid use disorder","volume":"76","author":"Koehl JL","year":"2019","unstructured":"Koehl JL, Zimmerman DE, Bridgeman PJ. Medications for management of opioid use disorder. Am J Health Syst Pharm. 2019, 76:1097-103. 10.1093\/ajhp\/zxz105","journal-title":"Am J Health Syst Pharm"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/HRP.0000000000000075","article-title":"Medication-assisted treatment of opioid use disorder: review of the evidence and future directions","volume":"23","author":"Connery HS","year":"2015","unstructured":"Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015, 23:63-75. 10.1097\/HRP.0000000000000075","journal-title":"Harv Rev Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/167312-association-of-medication-assisted-therapy-and-risk-of-drug-overdose-related-hospitalization-or-emergency-room-visits-in-patients-with-opioid-use-disorder","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:59:25Z","timestamp":1707508765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/167312-association-of-medication-assisted-therapy-and-risk-of-drug-overdose-related-hospitalization-or-emergency-room-visits-in-patients-with-opioid-use-disorder"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,26]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.44167","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,26]]}}}